This Week in Pharmacy

U.S. Supreme Court and Generic Drugs | TWIRx

This week, This Week in Pharmacy examines several stories shaping the business, clinical, and legal future of pharmacy practice. In TWIRx News from Pharmacy Times from Megan Maroney, PharmD, BCPP, FAAPP, focused on antidepressant use, withdrawal concerns, deprescribing, and shared decision-making. The key takeaway: patients should never stop antidepressants abruptly. Pharmacists can play a vital role in reducing stigma, educating patients, and supporting safe conversations about tapering, side effects, and long-term treatment. In health technology news, FDB research presented at the 2026 AMIA Amplify Informatics Conference found that patient-specific, risk-based medication guidance reduced pharmacy alert volume by 70% in a high-volume community pharmacy setting. The model consolidates alerts into one actionable message tied to the patient’s most relevant risk, helping reduce alert fatigue and improve workflow. Finally, we review a federal court ruling in Eli Lilly’s lawsuit against Houston-based Empower Pharmacy over compounded tirzepatide versions of Mounjaro and Zepbound. The judge dismissed key federal trademark and Texas unfair competition claims, while allowing other state claims to continue. Andy Crawford, with Keysource is back on TWIRx talking about the U.S. Supreme Court taking up Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., a case that could significantly affect generic drug competition. At issue is whether Hikma’s marketing materials and public communications around its generic version of Amarin’s fish oil-based cardiovascular drug improperly promoted a still-patented use. Hikma and the broader generic industry argue the case is about protecting “skinny label” rules, which allow generics to carve out patented indications while still bringing lower-cost medications to market. For pharmacists, the decision could influence generic availability, substitution confidence, pricing pressure, and how manufacturers communicate with providers and pharmacies. Thanks to our sponsors, CassianRx and IPC, for supporting independent pharmacy, innovation, and the future of patient-centered care.

Expanding Long-Term Care Pharmacy at Home, Delivery Logistics, AI, and Healthcare Misinformation | TWIRx

Sponsored by Rx4Route This Week in Pharmacy returns with a timely two-part episode focused on pharmacy operations, medication access, and the growing responsibility of healthcare communicators in the age of AI. In our first segment, we welcome Joseph Dymowski, PharmD, CEO of Centennial Pharmacy Services, and Doniyor Sattarov, Vice President of Operations at Rx4Route, for a conversation about expanding long-term care pharmacy at home. As more patients age in place, pharmacies must rethink delivery, logistics, documentation, and patient communication as essential parts of care. Delivery is no longer just a convenience. It is a critical extension of pharmacy services. Reliable routing, real-time tracking, and proof of delivery help pharmacies improve adherence, reduce operational friction, and build stronger trust with patients, caregivers, and providers. Expanding LTC pharmacy-at-home services, building scalable delivery workflows, improving route efficiency, using delivery technology to support compliance, and why logistics may become a major competitive advantage for pharmacies. This episode is sponsored by Rx4Route, pharmacy delivery software designed to help pharmacies streamline delivery operations, optimize routes, track orders, and improve proof-of-delivery workflows. In our second segment, we speak with **Vincent Grippi, CEO of Grippi Media, about the dangers of AI-generated misinformation and the higher standard required in healthcare communications. As AI becomes more common in content creation, communications professionals must protect accuracy, credibility, and patient trust. In healthcare, misinformation can influence clinical understanding, damage reputations, and create confusion across the industry. That is why content for healthcare professionals must be reviewed, verified, and guided by human judgment. AI misinformation in healthcare, responsible content development, source verification, editorial review, subject-matter expertise, and how communicators can use AI without sacrificing trust. This episode connects two critical forms of trust in pharmacy: operational trust at the patient’s door and informational trust across every communication channel. Featured Guests: Joseph Dymowski, PharmD— CEO, Centennial Pharmacy Services Doniyor Sattarov— Vice President of Operations, Rx4Route Vincent Grippi— CEO, Grippi Media

TJM Labs and Pharmacists in Politics | TWIRx

Congratulations to Logan Eury and his new wife Emily, got married today, May 1, 2026!  This C.O. Bigelow Collab Introduces the 188-Year-Old Pharmacy to a New Generation Abbode is taking over the Carolyn Bessette-Kennedy-approved shop for a month-long pop-up. https://fashionista.com/2026/05/co-bigelow-abbode-pop-up-carolyn-bessette-impact [https://fashionista.com/2026/05/co-bigelow-abbode-pop-up-carolyn-bessette-impact]  The article highlights how a pop-up and renewed interest in C.O. Bigelow has been fueled by the cultural resurgence of Carolyn Bessette-Kennedy’s minimalist style, amplified by media and social buzz. This renewed attention has driven significant foot traffic and sales, showing how storytelling, nostalgia, and “quiet luxury” aesthetics can translate into real retail impact.   Q&A: Mayo Clinic leaders share strategies for managing high-cost drugs without breaking the bank | Asembia AXS26 Summit https://www.managedhealthcareexecutive.com/view/q-a-mayo-clinic-leaders-share-strategies-for-managing-high-cost-drugs-without-breaking-the-bank-asembia-axs26-summit [https://www.managedhealthcareexecutive.com/view/q-a-mayo-clinic-leaders-share-strategies-for-managing-high-cost-drugs-without-breaking-the-bank-asembia-axs26-summit] Mayo Clinic leaders emphasize that managing high-cost drugs requires clear definitions, structured formulary review processes, and multidisciplinary collaboration to balance cost, access, and clinical value. They highlight the importance of evaluating safety, efficacy, financial impact, and site-of-care decisions together, while noting that non-340B systems face increasing pressure from rising costs and reimbursement constraints. Ultimately, success depends on stronger alignment between health systems, manufacturers, and payers to sustain access without compromising quality of care.  Where Gross-to-net Pressure Actually Lives After Launch Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. https://www.drugchannels.net/2026/05/where-gross-to-net-pressure-actually.html [https://www.drugchannels.net/2026/05/where-gross-to-net-pressure-actually.html] The article explains that “gross-to-net pressure” isn’t driven by a single factor, but by a combination of rebates, discounts, fees, and policy changes that continue to reshape how drug pricing actually works behind the scenes. As the industry shifts toward a “net pricing” model, traditional rebate-driven strategies are weakening, forcing manufacturers, PBMs, and pharmacies to rethink how value and profits are generated. Today's featured guest is Dr. Ndidiamaka Okpareke PharmD for Congress Dr. Ndidiamaka “Didi” Okpareke, PharmD, is a pharmacist, entrepreneur, and political candidate running for Congress in New Mexico’s 1st Congressional District. A first-generation Nigerian-American, she built her career in healthcare after graduating from the University of New Mexico College of Pharmacy and went on to found and lead a successful compounding pharmacy serving her community.  Motivated by nearly two decades of patient care experience, Okpareke entered the political arena to address challenges such as healthcare access, rising costs, and the shortage of providers in New Mexico. Running as a Republican, she emphasizes strengthening healthcare systems, supporting economic growth, and preserving opportunity for future generations, positioning herself as a community-focused leader bringing frontline healthcare insight into public policy.  This special episode highlights how TJM Labs is redefining pharmacy operations through AI-driven automation, bringing together insights from industry leaders Bhavesh Patel, PharmD—CEO of Carepoint Pharmacy—and Jonathan Adly, PharmD, MBA—CEO of TJM Labs. At the center of the conversation is how modern pharmacies are facing rising prescription volumes, staffing constraints, and increasing operational complexity, and why traditional manual workflows can no longer keep pace. TJM Labs addresses this challenge by deploying AI-powered “digital workers” that automate tasks like prescription intake, data entry, and patient communication—allowing pharmacy teams to shift their focus back to patient care and clinical decision-making.  Through the lens of both operator and innovator, the discussion explores how AI is not replacing pharmacy professionals, but augmenting them—reducing burnout, improving accuracy, and enabling scalable growth. With automation handling up to the majority of repetitive workload and delivering measurable ROI, TJM Labs represents a new model where technology and pharmacy expertise work together to create more efficient, patient-centered operations.

Healing the Sick Care System; Why People Matter | TWIRx

Guests: Gil Bashe Chair Global Health and Purpose at FINN Partners Maya Hajizada Chief Revenue Officer at Rx2Go C. Daniel Mullins Professor at University of Maryland School of Pharmacy Mina G Yacoub PharmD BCPS Founder & CEO at Qik Productions

Clearway Health, John Nosta, Perigon 360, and Psychedelics in Practice | TWIRx

TWIRx News: The FDA plans to remove 12 peptide bulk drug substances from Category 2 of the Section 503A compounding list after their nominations were withdrawn. For compounders, the key issue is that this change does not automatically make compounding these substances permissible, leaving pharmacies exposed to ongoing regulatory uncertainty until the FDA makes further decisions. A nationwide Class II recall has been issued for Xanax XR 3 mg tablets in 60-count bottles, lot 8177156, after the product failed dissolution testing. Pharmacists should immediately locate and quarantine affected stock while reminding patients not to stop benzodiazepine therapy suddenly without direction from a healthcare provider. Community pharmacies are taking on a larger role in wound care by serving as an accessible first point of contact for patients with minor injuries. Pharmacists can help assess wounds, recommend appropriate over-the-counter treatment, watch for warning signs of complications, and refer patients for higher-level care when needed. Special sponsor interview with Allison Arant with Clearway Health.  Featured interview with  the World's Leading Innovation Theorist John Nosta Guests & sponsors of today's TWIRx, Perigon 360 Pharmacy with Chris Antypas PharmD and ed Mills  And a bonus interview with Dr. Andy Krut PharmD, on Psychedelics (e.g., LSD, psilocybin, DMT)